Blair William & CO Blueprint Medicines Corp Transaction History

Blair William & CO

$33.4 Billion
Q3 2024

A detailed history of Blair William & CO transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Blair William & CO holds 6,512 shares of BPMC stock, worth $619,291. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,512

Previous 6,047 7.69%

Holding current value

$619,291

Previous $651,000 7.53%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$84.1 - $120.5 $39,106 - $56,032	465 Added 7.69%	6,512 $602,000
Q2 2024 Aug 12, 2024	SELL	$85.18 - $108.78 $48,467 - $61,895	-569 Reduced 8.6%	6,047 $651,000
Q4 2023 Feb 12, 2024	BUY	$43.96 - $92.84 $54,906 - $115,957	1,249 Added 23.27%	6,616 $610,000
Q2 2023 Aug 11, 2023	BUY	$42.2 - $66.37 $226,487 - $356,207	5,367 New	5,367 $339,000
Q3 2022 Nov 09, 2022	BUY	$49.93 - $77.7 $176,252 - $274,281	3,530 New	3,530 $233,000
Q2 2022 Aug 10, 2022	SELL	$45.23 - $70.15 $174,180 - $270,147	-3,851 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$54.1 - $110.08 $113,880 - $231,718	-2,105 Reduced 35.34%	3,851 $246,000
Q4 2021 Feb 14, 2022	BUY	$94.25 - $115.99 $37,794 - $46,511	401 Added 7.22%	5,956 $638,000
Q3 2021 Nov 12, 2021	BUY	$80.98 - $109.47 $201,316 - $272,142	2,486 Added 81.0%	5,555 $571,000
Q1 2021 May 13, 2021	SELL	$90.71 - $108.28 $17,869 - $21,331	-197 Reduced 6.03%	3,069 $298,000
Q4 2020 Feb 09, 2021	BUY	$92.08 - $124.48 $300,733 - $406,551	3,266 New	3,266 $366,000

Others Institutions Holding BPMC

# of Institutions

352

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.68B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Account